Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "IMA"

3208 News Found

Merck inks $200 million deal for Hengrui's midstage heart disease drug
News | March 26, 2025

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region


Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda
Healthcare | March 25, 2025

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%


Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
News | March 24, 2025

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes

Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)


J&J to break ground on new biologics facility in North Carolina
News | March 24, 2025

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases


Lupin bags EcoVadis Silver Medal for sustainability excellence
Sustainability | March 21, 2025

Lupin bags EcoVadis Silver Medal for sustainability excellence

Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring


Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%
Drug Approval | March 21, 2025

Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.


ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal
News | March 20, 2025

ZIM Laboratories receives marketing authorization for Dimethyl Fumarate in Portugal

Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis


UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025
Sustainability | March 20, 2025

UFlex’s FlexiTubes to showcase sustainable beauty packaging at COSMOPROF Italy 2025

FlexiTubes will showcase range of eco-friendly and innovative tube options


RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation
Drug Approval | March 19, 2025

RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation

Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes


Lupin receives tentative approval from USFDA for Amifampridine Tablets
Drug Approval | March 18, 2025

Lupin receives tentative approval from USFDA for Amifampridine Tablets

Amifampridine Tablets, 10 mg are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 years of age and older.